header logo image


Page 956«..1020..955956957958..970980..»

Brody: Time after a joint injury can fend off arthritis – Sarasota Herald-Tribune

August 22nd, 2017 5:54 am

By Jane Brody

When a physically active person like me injures a joint, especially one as crucial as a knee or ankle, one of the first thoughts is likely to be How fast can I get back to my usual activities?

That kind of thinking, however, could set the stage for a painful chronic problem years later: post-traumatic osteoarthritis.

In the rush to get back in the game whether as part of a team or elite sport or simply a cherished recreational activity like jogging or tennis it is tempting to short-circuit the rehabilitation needed to allow the joint to heal fully. But adequate recovery, including rehab measures aimed at strengthening structures that support the injured joint, is critical to maximize its stability, reduce the risk of re-injury and head off irreparable joint damage.

And you dont have to be a senior citizen to pay the price of failing to build up the tissues that help protect that joint. Studies have shown that when an adolescent or young adult suffers a knee injury, for example, X-ray evidence of arthritis is often apparent within a decade.

As a team of orthopedists and rehabilitation specialists from the University of Iowa explained, Recent research suggests that acute joint damage that occurs at the time of an injury initiates a sequence of events that can lead to progressive articular surface damage. That means deterioration of the surface of the bone itself and the connecting tissues that cushion and stabilize bones of a joint like the knee, which is what arthritis is all about.

Osteoarthritis afflicts some 27 million Americans, and that number will certainly grow with the increase in obesity, the current emphasis on lifelong physical activity and the aging of the population. It is a degenerative joint disease that occurs when the protective cartilage on the ends of bones and often the surface of the bones themselves wear down, causing pain, stiffness, instability and disability that can interfere with work and mobility and diminish quality of life.

The Iowa team noted that arthritis will eventually develop in more than 40 percent of people who seriously injure the ligaments (the stabilizing bands that connect bones to one another); the meniscus (the crescent-shaped cartilage that cushions the knee and certain other joints), or the articular surface of a joint. People with a history of trauma to the knee, for example, are three to six times more likely to develop arthritis in that knee. Even without an acute injury, highly repetitive impact on a joint can damage the articular cartilage.

This may help to explain why I ended up with bone-on-bone arthritis and had to replace both knees at age 63. I had suffered three ligament injuries (while skiing) and after years of running and singles tennis, the meniscus in both knees had shredded. Although I did the recommended physical therapy after each injury, I now know that I was not sufficiently diligent about maintaining the strength and flexibility of the supporting muscles and other tissues that might have better protected my knees for years longer.

A consensus statement in the Journal of Athletic Training said that arthritis should no longer be considered a disease that affects only the elderly.

Increasing evidence demonstrates that young and middle-age adults are suffering from osteoarthritis as well, the statement said. More than half of adults with symptomatic knee osteoarthritis are younger than 65.

In fact, as Joseph M. Hart, an athletic trainer who conducts clinical research at the University of Virginia, and his colleagues wrote in the journal, A 17-year-old athlete who tears her anterior cruciate ligament could develop osteoarthritis before she turns 30, potentially leading to chronic pain and disability. Damage to this ligament, in the center of the knee, is the most common injury among young athletes, especially girls, they wrote.

Jeffrey B. Driban, an athletic trainer at Tufts Medical Center in Boston, said that one person in three who injures the anterior cruciate ligament will have X-ray evidence of osteoarthritis within 10 years whether or not the injury is repaired surgically.

Driban and co-authors pointed out that some sports soccer, elite-level long-distance running, competitive weight lifting and wrestling are associated with a higher risk of knee injuries.

Sports participants who suffer a knee injury can minimize the risk of reinjury and arthritis, Driban said, by not rushing back into activity or trying to play through pain. They must strengthen the muscles that support the joint the quads, hamstrings and hip muscles. Its important to think about the entire lower extremity, not just the knee.

After an injury, an athletic trainer, rehabilitation specialist or physical therapist who specializes in orthopedics can evaluate a persons muscle strength, endurance, balance and movement quality, then guide recovery with a structured rehab program that is maintained for six to nine months, Hart said.

It is also important to continue to pursue an active lifestyle, said Abby C. Thomas of the University of North Carolina at Charlotte.

You may have to modify the activities you do, but you have to stay active to maintain strength and cardiovascular fitness without putting repetitive stress on a joint thats already injured, she said. If your knee hurts and you cant run, maybe get on a bike or swim, activities that place less stress on the knees.

Dont sit around on the couch because running hurts, Thomas said. Try walking, or something different, but dont give up on physical activity.

Lifelong activity is also important to prevent weight gain, since every extra pound places disproportionate stress on the knees. All the authors emphasized that pursuing a healthy lifestyle is crucial for everyone, not just elite athletes and those who play on school teams.

Go here to see the original:
Brody: Time after a joint injury can fend off arthritis - Sarasota Herald-Tribune

Read More...

Treatments for rheumatoid arthritis unique to individual patient … – Beatrice Daily Sun

August 22nd, 2017 5:54 am

Dear Doctor: We were shocked when our daughter, who is 26, was diagnosed with rheumatoid arthritis. I thought arthritis was something that elderly people got. What treatments are available and what are our daughter's prospects for an active and healthy life?

Dear Reader: We're very sorry to hear about the medical challenge your family is facing and hope the information we offer will be of help.

When it comes to what is commonly referred to as "arthritis," we're actually talking about two different conditions. Osteoarthritis, which is the type of arthritis you're thinking of in regards to a more elderly population, is a degenerative disease. In osteoarthritis, the tissues of the joints deteriorate due to wear and tear. When the cartilage that cushions the joints begins to break down, it leads to swelling, stiffness and pain.

Rheumatoid arthritis, or RA, is an inflammatory autoimmune disease. Joint damage occurs because the immune system has gone haywire and begins to target the body's own tissues. Although RA most commonly affects the joints, it can also involve other parts of the body, including the lungs, digestive system, circulatory system, skin and eyes.

In the United States, about 1.5 million people (more women than men) are living with RA. It generally doesn't appear until the 40s, and becomes increasingly common as we hit our 50s and beyond, but cases in younger people are not rare.

The most common sites of inflammation in RA are the wrists and the finger joints closest to the palm. However, the knees, neck, ankles, feet, elbows and shoulders can also be involved. RA has a symmetrical pattern, so the joint on each side of the body is usually affected. In addition to that symmetry, symptoms of RA include tender and swollen joints, a feeling of warmth within the joints, fatigue and occasional fever. For many people, prolonged morning stiffness or difficulty moving again following a long period of inactivity can be some of the early signs of RA.

Treatment is tailored to each person's symptoms. Your daughter's rheumatologist will discuss lifestyle changes to address inflammation. This includes using special tools or aids to help with difficult tasks, pursuing the right kind of exercise -- hatha yoga has been found to be helpful -- and striking the optimal balance between activity and rest.

Eating a well-balanced anti-inflammatory diet can help manage RA symptoms. This treatment approach got a boost recently when a study found that RA patients who ate fish twice a week (baked, steamed, raw or broiled, but not fried) scored measurably lower on a standardized scale that measures disease activity.

Some medications for RA address pain and inflammation. Others take aim at the disease process itself. All have potential side effects, so urge your daughter to learn the risks and benefits of any proposed medication.

Looking to the future, advances in immunotherapy and the expanding study of the ever-surprising gut biome offer hope for RA sufferers. In the meantime, prompt treatment is crucial. Make sure your daughter finds a good rheumatologist she likes and begins her medical care.

Eve Glazier, M.D., MBA, is an internist and assistant professor of medicine at UCLA Health. Elizabeth Ko, M.D., is an internist and primary care physician at UCLA Health.

Send your questions to askthedoctors@mednet.ucla.edu, or write: Ask the Doctors, c/o Media Relations, UCLA Health, 924 Westwood Blvd., Suite 350, Los Angeles, CA, 90095. Owing to the volume of mail, personal replies cannot be provided.

View original post here:
Treatments for rheumatoid arthritis unique to individual patient ... - Beatrice Daily Sun

Read More...

Rheumatoid arthritis didn’t stop Irwin man from enjoying the outdoors – Tribune-Review

August 22nd, 2017 5:54 am

Updated 7 hours ago

Carl W. Miller of Irwin started collecting guns in high school, became a marksman in the Army National Guard and spent more than 45 years teaching hunter/trapper courses in area sportsmen clubs.

He loved it, said his daughter Colleen Stubbs. He enjoyed (teaching) and they counted on him.

Mr. Miller became interested in firearms from when he could carry one in his hands, said his sister, Mary Ann Brown.

He reloaded his own ammunition. Shortly before his death, he was asking if she was interested in selling a Mossberg rifle owned by her late husband, she said.

It was his passion, she said.

Carl W. Miller died Friday, Aug. 18, 2017, in Excela Westmoreland Hospital. He was 82.

He was born July 11, 1935, in Arona, the son of the late Lawrence J. and Violet Miller.

He joined the Army National Guard in 1954 and attained the rank of sergeant in the 110th Infantry, his family said.

He was on active duty during part of his six-year enlistment.

Mr. Miller retired from CTP Carrera Inc. in Latrobe, where he was a quality assurance technician.

He was a member of American Legion Post No. 359 in Irwin and the National Rifle Association.

Her brother was a prankster who liked to wait until the tensest moment in a horror movie to yell boo, Brown said. He was a bundle of laughter and fun.

Diagnosed with rheumatoid arthritis in the 1960s, he didn't allow the inflammatory joint disease to stop him from participating in shooting competitions as well as hunting and fishing, his daughter said. He also made muzzleloaders.

He was still able to target shoot and be very, very good, so he was very proud of that, Stubbs said.

Mr. Miller occasionally hunted elk in Colorado, but mainly hunted deer, turkey and small game in Pennsylvania and fished for trout in area streams, said his son Eric Miller of Greensburg. He had 50 to 60 guns in his collection.

He also enjoyed camping and taking vacations in Hilton Head and the Outer Banks.

He was easygoing, his son said. He got along with everybody.

Their father was a social butterfly who developed an interest in photography and video in the 1960s, Stubbs said.

At family reunions, Christmas parties and other gatherings, he was the man with the video camera long before most people had them, she said.

He had his own darkroom and collected cameras, his family said.

Whenever he traveled, his camera was always with him, Stubbs said.

His memberships included the Irwin Sportsmen's Club, the White Oak Road and Gun Club and the McKeesport Sportsmen's Association.

He was a member of as many as he could join, she said.

Mr. Miller was preceded in death by his wife of 36 years, Martha G. (Lash) Miller. He is survived by their four children, Denise Sager of Mt. Pleasant; Christine Trout and her husband, W. Ronald, of Richland; Colleen Stubbs and her husband, Jeff, of Erie; and Eric Miller and his wife, Terri, of Greensburg; 12 grandchildren, and two great-granddaughters.

A funeral service will be held at 11 a.m. Tuesday at the Joseph W. Nickels Funeral Home, 404 Sewickley Ave., Herminie. Interment with full military honors will follow at Westmoreland County Memorial Park, 150 East Side Drive, Hempfield.

Memorial donations may be made to the Arthritis Foundation, 790 Holiday Drive, Green Tree, PA, 15220.

Brian Bowling is a Tribune-Review staff writer. Reach him at 724-850-1218, bbowling@tribweb.com or via Twitter @TribBrian.

Read more:
Rheumatoid arthritis didn't stop Irwin man from enjoying the outdoors - Tribune-Review

Read More...

Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results – Markets Insider

August 22nd, 2017 5:51 am

TEL AVIV, Israel, Aug. 21, 2017 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second quarter ended June 30, 2017.

"We are very pleased with our accomplishments in the first half of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. "As planned, 2017 is turning into a transformative year for Cellect Biotechnology. Cellect initiated its Phase I/II study on cancer patients undergoing matched related allogeneic HSCT transplantation and reported positive results in the first patient followed by the approval to recruit two more patients. Further, Cellect held a pre-IND meeting with the FDA that was very positive and Cellect is moving ahead with its plan to submit an IND".

Important progress was achieved with the company's IP portfolio the major patent covering the composition of matter and use of the ApotainerTm was issued in US and Russia, the collaboration with Entegris was further consolidated by receiving a BIRDF non-equity grant, and the development of the Apotainer was accelerated.

In addition, world renowned leaders joined the Company (i.e KOLs from Harvard Medical school, executives from Pfizer and Merck) and the Company teamed up with Boston based Locust-Walk business development group for planning and launching a business development campaign before the end of the year.

During the second quarter, the Company made the following announcements -

Recent Corporate Highlights:

Second Quarter 2017 Financial Results:

Balance Sheet Highlights:

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2017 (U.S. $1 = NIS 3.496).

The Company's consolidated financial results for the three and six months ended June 30, 2017 are presented in accordance with International Financial Reporting Standards.

About Cellect Biotechnology Ltd.

The Company is developing an innovative technology which enables the functional selection of stem cells based on their sensitivity to apoptosis. This functional-based selection is a breakthrough technology in the ability to isolate stem cells from any given tissue, and may improve a variety of stem cells applications.

The Company's first planned product line is expected to include unique containers for cell selection in an apoptosis-inducing microenvironment. Cellect's first planned commercial product candidate is a medical kit designed for the cancer treatment bone marrow transplantations market, as well as other markets which require cell selection. The Company plans that in the future its technology will be integrated in many production procedures of stem cell-based products.

The Company's securities are currently traded on both the NASDAQ Capital Market and the Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP").

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss our anticipated performance in 2017, the expected characteristics of our first product line, our beliefs about the future integration of our technology into the production procedures of stem cell-based products and the potential of our technology and its proposed uses. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2017

2017

2016

2017

2016

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

1,495

5,227

3,679

2,405

1,848

General and administrative expenses

1,729

6,046

3,547

3,497

1,617

Other income

-

-

(280)

-

(280)

Operating loss

3,224

11,273

6,946

5,902

3,185

Financial expenses (income) due to warrants exercisable into shares

1,519

5,312

-

(1,461)

-

Other financial expenses (income), net

135

468

23

161

(5)

Total comprehensive loss

4,878

17,053

6,969

4,602

3,180

Loss per share:

Basic and diluted loss per share

0.045

0.158

0.088

0.042

0.039

Weighted average number of shares outstanding used to compute basic and diluted loss per share

108,034,218

108,034,218

79,113,097

108,462,728

81,456,571

Cellect Biotechnology Ltd

Consolidated Balance Sheet Data

ASSETS

See the original post:
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results - Markets Insider

Read More...

Fatty liver can cause damage to other organs via crosstalk – Medical Xpress

August 22nd, 2017 5:51 am

Adipose cells (white/dyed red) next to an insulin-producing islet in the pancreas. Credit: IDM

Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis and liver cancer, but also the risk of type 2 diabetes and cardiovascular diseases. The cause for this is the altered secretion behavior of the fatty liver. It increasingly produces glucose, and unfavorable fats and proteins such as the hepatokine fetuin-A, all of which it releases into the bloodstream. Thus, the secreted substances of the fatty liver enter other organs and trigger further reactions. However, researchers did not know the effects of this "organ crosstalk," which organs are most affected, or what damage is caused by the hepatokine fetuin-A.

To elucidate the causal mechanisms and the resulting changes, researchers at the University of Tbingen studied the influence of fetuin-A on pancreatic adipose tissue. Approximately one-third of the pancreatic adipose tissue consists of adipose precursor cells (a type of stem cell) in addition to the mature adipose cells. If the pancreatic adipose cells are treated with fetuin-A in cell cultures, the mature adipose cells, in particular the adipose precursor cells in interaction with the islet cells, increasingly produce inflammation markers and immune-cell-attracting factors.

In addition, the researchers histologically analyzed tissue samples from 90 patients and found that the proportion of the pancreatic fat varied greatly. The number of defense cells of the immune system (monocytes/macrophages) was significantly increased in areas where many adipose cells had accumulated.

In a cohort of 200 subjects with an increased risk of type 2 diabetes, pancreatic fat content was measured by means of magnetic resonance imaging and compared with diabetes parameters. It was found that in persons who had already experienced a worsening of blood glucose regulation, an increased pancreatic fatty degeneration was associated with reduced insulin secretion. The investigations were carried out by Professor Hans Ulrich Hring and the Endocrinology Research Group, together with scientists from the Department of Experimental Radiology at the University of Tbingen.

These analyses, published in the journals Diabetologia and Diabetes/Metabolism Research and Reviews, suggest that a fatty liver, together with a fatty degeneration of the pancreas, triggers increased local immune cell infiltration and inflammation that accelerate the course of the disease.

However, adipose tissue is not harmful per se. It can even have protective effects. For example, adipose tissue located around blood vessels or the kidney has regenerative properties. "The factor that leads to pathological changes is fetuin-A, which is produced by the fatty liver," said Tbingen Professor Dorothea Siegel-Axel. As a result, instead of protecting tissue as before, the adipose tissue elicits inflammatory processes. This leads to a restriction of renal function. This is demonstrated by studies on arteries and the kidney, which have recently been published by the working group in the journal Scientific Reports.

"The statement that obesity in itself always has a disease-causing effect is too imprecise. Not until further parameters have been determined, such as fatty liver and hepatokine levels, as well as the elicited changes in other organs, can we obtain more exact indications as to whether a person has an increased disease risk or not," said Professor Hring, board member of the DZD and director of the IDM, summarizing the current results.

Explore further: Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients

More information: Felicia Gerst et al, Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion, Diabetologia (2017). DOI: 10.1007/s00125-017-4385-1

Journal reference: Diabetologia Scientific Reports

Provided by: Deutsches Zentrum fuer Diabetesforschung DZD

Read more:
Fatty liver can cause damage to other organs via crosstalk - Medical Xpress

Read More...

Stem cells could benefit cockapoo’s knee issue – Albuquerque Journal

August 22nd, 2017 5:51 am

.......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........

Dr. Nichol: If your cockapoo has somewhat bowed rear legs, one or both of her knee caps (patellas) may slip out of its groove at the lower end of her thigh bone. Some patellas dislocate (luxate) just occasionally. A dog may skip for a few steps and then use the leg normally again after the patella slips back into the groove.

The knees of a dog with luxating patellas are vulnerable to injury. Your girls missed jump may have strained the supportive tendons that guide her patella. Rest and anti-inflammatory medication can help in the short term but the anatomy would still be structurally unsound. The only permanent solution will be surgical remodeling of the attachment of her patella and the groove in her lower femur.

Called a tibial crest rotation this surgery is a long-established procedure that many veterinarians are skilled at performing. But even with the geometric forces corrected, some chronic damage to a dogs tendons and cartilage will remain. Thats what makes stem cell therapy valuable.

While your girl is under anesthesia for knee surgery her doctor can make a small abdominal incision and remove a bit of fat. Your dogs very own stem cells (no risk of rejection) will be processed and shipped back overnight for injection into her knee. Over the following weeks the stem cells will stimulate regeneration of chronically inflamed tissues, resulting in a stronger and more comfortable joint.

Finally, stem cell therapy, also known as regenerative medicine, is not new. Veterinary orthopedists have used stem cells for 15 years to speed healing and reach better long-term outcomes.

Each week I make a short video or podcast to help bring out the best in pets. Sign up at no charge on my website, drjeffnichol.com. Every Tuesday it will arrive in your email. Ill also send you my free Pet Emergency and CPR guide.

Dr. Jeff Nichol treats behavior disorders at the Veterinary Emergency & Specialty Centers in Albuquerque and Santa Fe (505-792-5131). Questions on pet behavioral or physical concerns? For answers, Like my Facebook page at facebook.com/drjeffnichol or by mail to 4000 Montgomery NE, Albuquerque, NM 87109.

See the original post here:
Stem cells could benefit cockapoo's knee issue - Albuquerque Journal

Read More...

ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe – Markets Insider

August 22nd, 2017 5:51 am

PALM DESERT, Calif., Aug. 21, 2017 /PRNewswire/ --ASC Biosciences, Inc. (formerly Nevis Capital Corporation) ("ASC") (OTC Pink Open Markets: "ASCW") is pleased to announce it will appear on the award-winning program "Informed" hosted by Rob Lowe.

Informed is an award-winning program that highlights new stories and innovated concepts through ground breaking short-form and long-form documentary presentation. The program, which is anchored by a veteran production team with decades of industry experience, is able to effectively communicate the most critical stories to a wide and diverse audience. "Informed" is hosted by the inimitable Rob Lowe.

ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company that has a proprietary adult stem cell platform capable of forming nearly every tissue in the human body. These cells, Multipotent Adult Stem Cells ("MASCs"), will differentiate into cartilage, bone, tendon, muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans. MASCs have apparent unlimited proliferation potential (do not reach replicative senescence) and have been shown to regenerate tissues by differentiating into the cell types at the site. MASCs lack the ability to cause a rejection response, and can thus be used as an allogenic transplant - which means that cells harvested from a single donor can be expanded in culture and the expanded cells can be used to treat hundreds, thousands, or millions of patients. TheMissionof ASC Biosciences is to provide surgeons around the world with our proprietary brand of unlimited allogeneic "Stem Cells in a Bottle" to be used in a wide variety of FDA Approved orthopedic and cosmetic therapies, resulting in permanent tissue regeneration; thus avoiding the repeat treatments commonly required in the current generation of approved stem cell therapies. ASC intends to establish an intellectual property portfolio that will provide proprietary dominion in the repair and regeneration of all human tissues. For more information visit:http://www.ascbio.comor @ASCbio1 on Facebook.

ASC trades on the OTC Pink Open Markets under the symbol: ASCW.

Forward-Looking StatementsCertain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about ASC Biosciences, Inc. industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.

Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Readers should review carefully reports or documents the Company files periodically with the OTC Markets -https://www.otcmarkets.com.

View original content:http://www.prnewswire.com/news-releases/asc-biosciences-inc-to-appear-on-the-informed-series-hosted-by-rob-lowe-300507183.html

SOURCE ASC Biosciences, Inc.

Read this article:
ASC Biosciences, Inc. to appear on the "Informed" series hosted by Rob Lowe - Markets Insider

Read More...

America is genuinely worried it went blind today – VICE News

August 22nd, 2017 5:50 am

If you can still read this, congratulations youre not blind from staring directly into the eclipse (yet).

Then again, eye damage from viewing a solar eclipse can take days to manifest. Using whatever eyesight they had left, freaked out Americans turned to Google for advice.

Google Trends showed a sharp uptick in searches for SEO-friendly phrases like solar eclipse headache, solar eclipse blind, eyes hurt, seeing spots, solar retinopathy, headache after eclipse, accidentally looked at eclipse, headache after solar eclipse, burned retinas, eclipse headache, and eclipse blind.

Experts warn that staring into a solar eclipse for any amount of time even just a few seconds could result in permanent blurry vision or blindness because the dark moon passing over the sun essentially cancels out the normal burning sensation that makes people look away from bright light.

Its often hard to tell whether damage has occurred, since the exposure is painless and symptoms can crop up for weeks afterward. Symptoms that suggest short-term damage include eye pain and light sensitivity, often occurring within 24 hours of exposure, Linda Chous, an ophthalmologist and chief eye care officer for UnitedHealthcare, told NBC. Long-term symptoms include a loss of central vision including a dark spot or hole in vision typically presenting anytime up to two weeks after exposure.

But sadly for President Donald Trump, who was photographed looking directly into the eclipse twice in a span of less than five minutes, Americans seem less concerned with his ocular health.

Searches for Trump blind actually peaked in November 2016 around the same time he promised to put his businesses into a blind trust in an effort to prevent a conflict of interest between the White House and the Trump Organization.

In that sense, Trump does not appear to be blind at all according to Propublica, the trusts terms have since been changed to allow Trump to withdraw money from the businesses whenever he wants.

See original here:
America is genuinely worried it went blind today - VICE News

Read More...

Here Are the Eye Damage Symptoms to Worry About After Watching the Eclipse – Thrillist

August 22nd, 2017 5:50 am

The website PreventBlindness.org, an organization committed to education around blindness and "bringing Americans to eye care," has published a handy guide to safely viewing a solar eclipse and what it can potentially do to your eyes if they aren't shielded by the proper protection. As PreventBlindness.org explains, looking at a solar eclipse too long can cause "solar retinopathy," or retinal burns that destroy the cells that help you see. Unfortunately, the damage occurs with no pain, due to the fact that there are no nerve endings in that part of your eyes, and it can take "a few hours to a few days after viewing the solar eclipse to realize the damage that has occurred."

All of which sounds absolutely terrifying, an information cocktail that seems like a surefire rocket fuel to the planet Hypochondria. Still, you can never be too careful, especially if you're already experiencing discomfort in the eyes. These are the specific symptoms PreventBlindness.org stipulates that you should look out for:

See the article here:
Here Are the Eye Damage Symptoms to Worry About After Watching the Eclipse - Thrillist

Read More...

Letter: Political blindness and the total eclipse – INFORUM

August 22nd, 2017 5:50 am

Perhaps some of the region's climate-change deniers even readand believedan article appearing in The Forum ('Fargo-Moorhead will be in path of total solar eclipse in 2099'). To be specific, this eclipse will begin at 10:37 a.m. on Monday, Sept. 14, 2099.

That calculation is the result of engineering and astronomy, or in a word: science.

So, why might some climate-change deniers, such as Inhofe, blindly confess that God controls our climate, but then have no problem believing that mani.e., the scientific methodis capable of predicting celestial events decades away down to the very minute?

Follow the money. Citing Oil Change International, the website DeSmogBlog asserts that Inhofe has received more than $2 million in political contributions from the coal and oil industry. One of his top benefactors is Koch Industries ($77,550 since 1999). ExxonMobil has contributed more than $35,000 since 1999.

But Oklahoma is a long way from North Dakota. Surely, that type of financial support doesn't cloud our politicians' vision, right?

Well ... according to OpenSecrets.org, Sen. John Hoeven received $492,228 from the energy/natural resources sector (oil and gas, electric utilities and mining industries) during the 2015-2016 cyclean amount placing him among the top-20 recipients in Congress. At the same time, Sen. Heidi Heitkamp received $155,155 and Rep. Kevin Cramer received $337,200.

Oh, by the way, OpenSecrets.org says Inhofe received only $64,000 from the energy/natural resources sector during the same period.

Hulse lives in Fargo.

More:
Letter: Political blindness and the total eclipse - INFORUM

Read More...

Eclipse Can Cause Blindness, Other Damage | CBN News – CBN News

August 22nd, 2017 5:50 am

Watch CBN News' Lorie Johnson and Mark Martin's interview on viewing the eclipse safely to see the type of glasses to get or creating your own "projector."

Looking at the solar eclipse without properly protecting your eyes can cause permanent eye damage and other issues. The only exception is during the brief one to three minutes of totality, when the moon completely covers the sun.

The sun can damage the retina, which is in the back of the eye, and contains light sensors that allow us to see.The amount of damage our retina sustain depends on how long we look at the sun and where the sun is in the sky. It's less intense close to the horizon, most insense directly overhead.

Our retina can handle indirect light from the sun just fine. However, since the sun's light is so intense, looking directly at it can literally burn our retina. This is true regardless of whether there is an eclipse. The difference is, on most days we instinctively avert our eyes when looking directly at the sun. It's a reflex because it's uncomfortable. However, during an eclipse, many people forego the discomfort of staring directly at the sun for the thrill of the witnessing an eclipse.

People tend to rationalize that since the moon is covering some, or most, of the sun, it's safe to view directly with the naked eye. Not so, say eye doctors who treated burned retinas in the shape of crescents after the 1979 solar eclipse.

Usually retina damage isn't noticed until the next morning. A person might look in the mirror and have difficulty making out their facial features, or attempt to read the newspaper without being able to read the words. Doctors say about half of the people with burned retinas regain all or part of their vision within six months. Other times it's permanent.

Sadly, counterfeit eclipse glasses are being circulated. The safe ones must be marked as certified by the International Organization for Standardization (ISO). The glasses should say they meet "ISO 12312-2" safety standards. The glasses will look completely black when you look through them unless you are looking at the sun.Dark sunglasses and even welders glasses do not offer enough protection.

If you do not have proper eclipse glasses, you can safety view the eclipse through a do-it-yourself pinhole projector. Punch a hole in a piece of cardboard. Then tape a piece of foil over the cardboard. Using a pin or tack, poke a small hole in the foil over the hole in the cardboard. Hold the device perpendicular to the sun. View the image on the ground or a screen. Do not look directly at the sun through the pin-hole projector.

Safety experts are urging drivers to use extreme caution on the roads during the eclipse and refrain from looking at the spectacle in the sky rather than the road.

Read the original:
Eclipse Can Cause Blindness, Other Damage | CBN News - CBN News

Read More...

STONE: Certain medical practices can prey on false hopes – Odessa American

August 22nd, 2017 5:50 am

Its human nature to want a quick fix in resolving issues or problems. Getting maximum results with minimal effort certainly has its appeal. From Thigh Masters and Bowflexes to The Clapper and Ginsu knives, the promise for rapid results and convenience can draw consumers in like the late-night glow of the TV infomercials selling these items.

But, lets be honest, these examples may have yield their desired results, but most products end up being a total disappointment and waste of money. This is also the case with certain medical procedures or therapies claiming to fix certain ailments or chronic conditions. As a patient-consumer, its important to do your research and not let emotions or false hopes guide you into making a potentially expensive or even risky decision involving your health.

One item in general, stem cell therapy, has been getting quite a bit of attention of late. Many may ask, what are stem cells? Stem cells are cells that have the potential to develop into many different types of cells. Think of them as a blank canvas which can divide and become specialized cells within the body such as blood, liver, or muscle cells. Stem cell therapy acts by introducing these cells into some areas of the body, to which the stem cells can divide regularly to regenerate and/or repair existing tissue. Stem cell therapy has long been used by physicians to treat certain types of cancers, such as leukemia and lymphoma as well as treating some bone, skin, and corneal eye injuries. But, while stem cells continue to be studied as potential treatments for other ailments and conditions, there are very few of these treatments currently that have been proven to be effectivelet alone safe.

With catchy, even gimmicky, tag lines like make me walk again, feel young again, or no surgery, no side effects, clinics (both in the United States and outside of it) are offering stem cell therapy to treat a laundry list of conditions. The problem with it is patient testimonials and gimmicky marketing techniques can be misleading. One resource beneficial in better understanding stem cell therapies is the International Society for Stem Cell Research (ISSCR). It represents academia and industry on a broad range of issues that affect the well-being of patients and their families, and strives to educate the public and government regulators on the basic principles of stem cell science and the realistic potential for new medical treatments and cures.

According to the ISSCR, when there is no existing or effective treatment for a disease or condition it is easy to understand why you may feel there is nothing to lose from trying something new, even if it isnt proven. Unfortunately, most of the unproven stem cell treatments for sale throughout the world carry very little promise of actual benefit and very real risks.

Many stem cell therapy clinics may offer the use of a patients own cells, also known an autologous transplant. In theory, your immune system would not attack your own cells if they were used in a transplant. However, the processes by which the cells were acquired, grown and then reintroduced into the body would carry risks. Here are just a few known risks of autologous stem cell treatments:

If you have thought about or are considering stem cell therapy, first get the guidance of your primary healthcare provider. They can help guide you in obtaining the right literature and evidence in help making the right decision for the safest and most effective treatments available. Snake oil salesmen exist in every industryincluding those wearing white lab coats. Choose your care wisely.

Continued here:
STONE: Certain medical practices can prey on false hopes - Odessa American

Read More...

ViraCyte Awarded $8.99M from the Cancer Prevention and … – Markets Insider

August 22nd, 2017 5:50 am

HOUSTON, Aug. 17, 2017 /PRNewswire/ --ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe viral infections, today announced notification of funding approval for a Product Development Research grant totaling $8.99 million by the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee to support the clinical development of the Company's lead product, Viralym-M a "ready to administer" multivirus-specific T cell immunotherapy.

Under the Product Development Research Program, CPRIT supports Texas-based companies and institutions by funding projects developing disruptive, commercially-oriented technologies with the overall goal of improving outcomes in patients with cancer. Pending successful negotiations and contract execution, the CPRIT award, entitled Improving Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells, will support an advanced clinical trial testing the safety and efficacy of Viralym-M in adult and pediatric cancer patients.

"ViraCyte is dedicated to improving the outcomes of stem cell transplant recipients and further developing T cell immunotherapy for viral complications for which there are no currently approved treatments available," stated Dr. Ann Leen, Chief Scientific Officer at ViraCyte. "We are extremely grateful to CPRIT and the Oversight Committee for their positive review and funding recommendation of this award."

About ViraCyte, LLC

ViraCyte's current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte's lead T cell products are in Phase 2 and Phase 1 clinical trials, with effectiveness rates of greater than 94% in patients who have failed conventional therapy. More information can be found atwww.viracyte.com

ViraCyte is a resident company at JLABS @ TMC, Houston, Texas.

View original content:http://www.prnewswire.com/news-releases/viracyte-awarded-899m-from-the-cancer-prevention-and-research-institute-of-texas-300506283.html

SOURCE ViraCyte, LLC

Excerpt from:
ViraCyte Awarded $8.99M from the Cancer Prevention and ... - Markets Insider

Read More...

Engagement and Events Officer – The Conversation AU

August 22nd, 2017 5:50 am

Department of Anatomy and NeuroscienceFaculty of Medicine, Dentistry and Health Sciences

Salary: $68,892 - $79,130 p.a. plus 9.5% superannuation

Stem Cells Australia (SCA), is a multi-million dollar research initiative supported by the Australian Research Council and several research institutions across Australia. The Centre for Stem Cell Systems (CSCS) was formed in 2016 to facilitate interdisciplinary collaboration between stem cell researchers in the Parkville Precinct, which encompasses the University and affiliated medical research institutes. Together, SCA and CSCS aim to support and promote high quality stem cell research and lead public discussion about the important ethical, legal and societal issues associated with stem cell science.

The Engagement and Events Officer will help build and deliver an effective communications and engagement strategy, including website maintenance, newsletter content and distribution, event coordination, and other outreach activities. The incumbent will work closely with the executive teams of SCA and CSCS to develop promotional content and to develop communication portfolios to meet the needs of our dynamic research network.

Close date: 5 Sep 2017

Position Description and Selection Criteria

0043864.pdf

For information to assist you with compiling short statements to answer the selection criteria, please go to our website.

Read more:
Engagement and Events Officer - The Conversation AU

Read More...

Sperm from stem cells could help some types of male infertility – BioNews

August 22nd, 2017 5:50 am

Cells from genetically infertile male mice have been turned into sperm, and used to produce healthy pups.

Researchers hope the technique could one day help men with certain causes of infertility. Experts hailed the work as 'very encouraging' and 'fascinating science', while noting that the technique is experimental only, and raises ethical and legal considerations should it be developed for humans.

'Our approach allowed us to create offspring from sterile XXY and XYY mice,' says first author Dr Takayuki Hirota at the Francis Crick Institute in London. 'It would be interesting to see whether the same approach could one day be used as a fertility treatment for men with three sex chromosomes.'

Having an extra sex chromosome three instead of two can cause infertility in mice and men. In humans, about onein 500 men may have either an extra X chromosome (Klinefelter's syndrome) or an extra Y chromosome (Double Y) in their genomes.

British and Japanese researchers aimed to removethe extra sex chromosome in infertile male mice with this problem. They took cells from the ears of the mice and cultured them in the lab to collect fibroblast (connective tissue) cells. They then coaxed the fibroblast cells into iPS (induced pluripotent stem) cells in the process some of the cells lost their extra sex chromosome.

Using specific chemical signals, the researchers could guide these stem cells into becoming the cells which can develop into sperm. When these were transplanted into the testes of live mice, they matured into sperm, which were used in assisted reproduction to give healthy pups.

Others agree the study offers potential. 'Although a mouse study, this research is exciting, since it raises the future possibility that sperm without the extra X chromosome could be made,' saidDr Channa Jayasena, a reproductive endocrinologist at Imperial College London. 'This could offer potential hope for affected couples.'

Indeed, a preliminary experiment by the researchers turning fibroblast cells from men with Klinefelter's syndrome into stem cells in vitro managed to lose the extra X chromosome.

But, Dr Jayasena notes the new study 'raises important ethical issues'.

Professor Allan Pacey at the University of Sheffield, UK, said: 'This is very encouraging. The only fly in the ointment is that currently the use of such sperm in the UK is not lawful and it would take a change of primary legislation to allow us to use such sperm in infertility treatment.'

While praising the study, Professor Adam Balen, chair of the British Fertility Society, said its application in improving fertility in men with Klinefelters syndrome 'is a long way off clinical practice'.

He also noted: 'Furthermore there are possible significant risks outlined in the paper which mean that any therapeutic application is far from certain.'

The study, published in Science, found that when the cells were transplanted into the testes of mice, some of the animals developed teratomas.

The rest is here:
Sperm from stem cells could help some types of male infertility - BioNews

Read More...

Will CRISPR fears fade with familiarity? – Albany Times Union

August 22nd, 2017 5:50 am

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Patricia Stapleton, Worcester Polytechnic Institute

(THE CONVERSATION) The first test-tube baby made headlines around the world in 1978, setting off intense debate on the ethics of researching human embryos and reproductive technologies. Every breakthrough since then has raised the same questions about designer babies and playing God but public response has grown more subdued rather than more engaged as assisted reproductive technologies have become increasingly sophisticated and powerful.

As the science has advanced, doctors are able to perform more complex procedures with better-than-ever success rates. This progress has made in vitro fertilization and associated assisted reproductive technologies relatively commonplace. Over one million babies have been born in the U.S. using IVF since 1985.

And Americans acceptance of these technologies has evolved alongside their increased usage, as weve gotten used to the idea of physicians manipulating embryos.

But the ethical challenges posed by these procedures remain and in fact are increasing along with our capabilities. While still a long way from clinical use, the recent news that scientists in Oregon had successfully edited genes in a human embryo brings us one step closer to changing the DNA that we pass along to our descendants. As the state of the science continues to advance, ethical issues need to be addressed before the next big breakthrough.

Louise Brown was born in the U.K. on July 25, 1978. Known as the first test-tube baby, she was a product of IVF, a process where an egg is fertilized by sperm outside of the body before being implanted into the womb. IVF opened up the possibility for infertile parents to have their own biologically related children. But Browns family was also subjected to vicious hate mail, and groups opposed to IVF warned it would be used for eugenic experiments leading to a dystopian future where all babies would be genetically engineered.

The reaction in the U.S. had another layer to it when compared to other developed countries. Here, research on embryos has historically been linked to the debate on abortion. The 1973 Supreme Court decision to make abortion legal in Roe v. Wade fueled anti-abortion groups, who also oppose research on human embryos.

Embryonic research and procedures offer the hope of eliminating devastating diseases, but scientists also destroy embryos in the process. Under pressure from these groups over the ethical implications of embryo creation and destruction, Congress issued a moratorium in 1974 on federally funded clinical research on embryos and embryonic tissue, including on IVF, infertility and prenatal diagnosis. To this day, federal funds are still not available for this type of work.

In hindsight, the sharp media attention and negative response from anti-abortion groups to IVF didnt accurately represent overall public opinion. The majority of Americans (60 percent) were in favor of IVF when polled in August 1978, and 53 percent of those polled said they would be willing to try IVF if they were unable to have a child.

So while the intense media coverage at the time helped inform the public of this new development, the insensitive labeling of Louise Brown as a test-tube baby and warnings about dystopian results didnt stop Americans from forming positive opinions of IVF.

In the nearly 40 years since IVF was introduced for use in humans, scientists have developed several new technologies from freezing eggs to genetically testing embryos before implantation that have improved patient experience as well as the chances that IVF will result in the birth of a baby. The announcement of each of these breakthroughs has resulted in flurries of media attention to the ethical challenges raised by this type of research, but there has been no consensus social, political or scientific on how to proceed.

Americans general opinion of assisted reproductive technologies has remained positive. Despite opposition groups efforts, surveys show that Americans have separated out the issue of abortion from embryonic research. A Pew Research Center poll from 2013 revealed that only 12 percent of Americans say they personally consider using IVF to be morally wrong. Thats a significant decrease from the 28 percent of respondents in 1978 who replied that they opposed the procedure for being not natural. In addition, the 2013 poll showed that twice as many Americans (46 percent) said they do not personally consider using IVF to be a moral issue compared to the number of Americans (23 percent) who said they personally do not consider having an abortion to be a moral issue.

Although most Americans dont think of embryonic research and procedures like IVF as a moral issue or morally wrong, the introduction of new technologies is outpacing Americans understanding of what they actually do.

Polls from 2007-2008 showed that only 17 percent of respondents reported that they were very familiar with stem cell research, and that there was a relative absence of knowledge about even the most prominent of the embryo-research issues. When Americans are asked more specific questions that explain IVF, they show less support for certain procedures, like freezing and storing eggs or using embryos for scientific research.

In light of recent developments, surveys show that nearly 69 percent of Americans have not heard or read much or know nothing at all about gene editing. Additionally, support for gene editing depends on how the technology will be used. A majority of Americans generally accept gene editing if the purpose is to improve the health of a person, or if it will prevent a child from inheriting certain diseases. The scientists in Oregon used a gene-editing technique that allowed them to correct a genetic defect in human embryos that causes heart disease. This type of progress falls into the category that most Americans would support.

But the technique thats used to make this correction, known as CRISPR-Cas9, can potentially be used for editing genes in other ways, not just to eliminate diseases. The success of the Oregon team opens the door to many possibilities in gene editing, including ones unrelated to health, such as changes to appearance or other physical characteristics.

Advancements in assisted reproductive technologies have happened rapidly over the last few decades, leading to over five million births worldwide. But as common as these procedures have become, scientists are not yet in agreement over how to integrate CRISPR and gene editing to the IVF toolkit. There are concerns about changing the genomes of human embryos destined to be babies, particularly since any modifications would be passed on to future generations. Scientific committees have noted that decisions on whether and how to use gene editing should be revisited on a regular basis. The newest breakthrough with CRISPR is providing us with one of those opportunities.

We should focus our attention on answering the ethical questions that have long gone unanswered: What are the boundaries to this type of research? Who decides what is an ethical use of CRISPR? What responsibility do we have to people affected by genetic conditions? Who pays for these medical procedures? How will this research and potential clinical use be regulated?

The successful use of assisted reproductive technologies has skyrocketed in the last decade, making Americans complacent about some of the ethical concerns that these procedures raise. Its important that we engage with these issues now, before gene editing becomes as familiar to us as IVF.

This article was originally published on The Conversation. Read the original article here: http://theconversation.com/will-crispr-fears-fade-with-familiarity-82419.

Excerpt from:
Will CRISPR fears fade with familiarity? - Albany Times Union

Read More...

Spark’s Gene Therapy SPK-8011 to Treat Hemophilia A and B Advance in Clinical Trials – Hemophilia News Today

August 22nd, 2017 5:49 am

Three patients who received SPK-8011 a gene therapy developed by Spark Therapeutics for hemophilia A show increased production of clotting factor VIII without any safety issues reported, says the company.

The patients are the first to receive the treatment as part of a Phase 1/2 clinical trial, with early data showing they have not yet experienced spontaneous bleeding episodes.

The encouraging start of our SPK-8011 clinical trial reinforces the strength of our gene therapy platform, delivers human proof-of-concept in a second liver-mediated disease a significant achievement in the gene therapy field and positions us well to potentially transform the current treatment approach for this life-altering disease with a one-time intervention, Katherine A. High, president and CEO of Spark Therapeutics, said inreleasingsecond-quarter 2017 financial results.

The study (NCT03003533) examines escalating doses of the treatment a one time infusion of a non-infectious virus that delivers a functional copy of the gene encoding clotting factor VIII.

The first two patients received the lowest dose and have now been followed for 23 weeks and 12 weeks. Measurements show their levels of the clotting factor steadily rising, reaching a stable level of 11 and 14 percent of normal values. Withthose results in hand, researchers decided to go for a higher dose in the third patient. So far, the increase of factor VIII in that third patient is higher than that observed in the other two, corresponding to the increased dose.

Researchers have not detected immune reactions to the therapy in any of the patients. This is important, as antibodies to SPK-8011 ould potentially render it ineffective.No serious adverse events have been reported and none of the patients required treatment with corticosteroids.

Spark, based in Philadelphia, has also reported on its second gene therapy, SPK-9001, now being developed to treat hemophilia B.

Researchers presented data from the Phase 1/2 study (NCT02484092) at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress, showing that the 10 participants had lowered their annual bleeding rate by 96 percent. They also lowered their annualized infusion rate by 99 percent.

In addition, their levels of clotting factor IX, 12 weeks after the treatment, had stabilized at 33 percent. Four of the patients have been followed for more than a year after the treatment, and one for as long as 18 months.

None have developed immune reactions to the treatment and no bleeding episodes have been recorded. One patient with severe joint disease had precautionary factor infusions for persistent knee pain.

We are excited about the progress we are making to achieve our goals of our investigational hemophilia A and B programs: to safely achieve predictable, consistent and sustained activity levels that prevent spontaneous bleeding, said High.

Go here to read the rest:
Spark's Gene Therapy SPK-8011 to Treat Hemophilia A and B Advance in Clinical Trials - Hemophilia News Today

Read More...

Should scientists be on social media? Meet the groundbreaking Saudi researcher who thinks so – Arab News

August 21st, 2017 12:44 pm

DUBAI: Nouf Al-Numair, a jet-setting young scientist from Riyadh, is working tirelessly to encourage Saudi youths to take an interest in science, technology, engineering and math (STEM).She could be the perfect role model for those who wish to make a name for themselves in the field, especially considering her call for lab-bound scientists to get out there and show off their achievements on social media.She obtained an MSc and a Ph.D. in bioinformatics and molecular genetics from University College London (UCL).Despite still being in her early 30s, she now works as a bioinformatics and molecular genetics scientist at King Faisal Specialist Hospital and Research Center.She is also an assistant professor at the College of Medicine at Alfaisal University, and is engaged in volunteer work.After pursuing her undergraduate studies in Saudi Arabia, Al-Numair headed to the UK. After my internship at King Faisal Specialist Hospital and Research Center, I spent time rotating between different labs, she told Arab News.It was then that I realized I wanted to explore how two different scientific fields the pathology of molecular genetics and the technology of computer science could merge. At the time of my placement, this approach wasnt available at universities and hospitals in Saudi Arabia.But the fashionable scientist, with perfectly-coiffed hair and a chic abaya, insists the move was about so much more than just her academic dreams.Going abroad and studying there, living there and exposing myself to a different education will enrich me as a person, she said.Everyone can access knowledge on the Internet, in books but the experience itself is one of the main reasons.Al-Numair is especially grateful to her family for supporting her desire to pursue her dream. When a family sees potential, they should really take care of it and polish it to convert this interest into a real thing, she said.But young aspiring innovators who do not have family support should still follow their passions, as it is up to the individual to make it work, she added. I wasnt taught this dream or passion, I practiced it.Al-Numair is now one of the first Saudi scientists to major in molecular genetics and programing biological information, a precise science that enables practitioners to read the future of diseases before they come into existence through genetic mutation.She uses more than seven programing languages to analyze human genes. She has published several papers and has spoken at multiple international conferences.Since I was young, I always thought of myself as a creator, an innovator. Even then, I wanted to be a pioneer of an interesting field, she said.In 2014, Al-Numair was honored by the Saudi ambassador to the UK in a ceremony celebrating outstanding students for their scientific achievements.She decided to return to the Kingdom to pursue a career in STEM as Saudi Arabia is my birth country. Who does not want to return home?In the Kingdom, she works tirelessly to encourage interest in the science and technology sector. Im a member of the MiSK youth community (the Prince Mohammed bin Salman bin Abdul Aziz Foundation). MiSK focuses on the countrys youth and provides different means of fostering talent, creative potential and innovation that paves the way toward opportunities in the arts and sciences, she said, calling on more young people especially women to take part.I hope that more Saudi and Arab women will join the field. This is why Im participating in the #Championofscience campaign and developing videos with the British Council. Were doing this because we believe its important to shed more light on stories of incredible women working in STEM, to inspire the next generation of girls to become leading scientists.British Councils across the Gulf are working to highlight Arab women working in STEM who are making a real difference in terms of research and innovation in their countries.The council invited participants, including Al-Numair, to film a short video explaining why they chose to follow their dreams, in a bid to encourage young people to show an interest in STEM.Writing is good as you can express yourself, but a video, even if its only one minute youre speaking the language of the young generation, and with social media its crazy now, Al-Numair said of the campaign.We as scientists should be out there more. We should use social media and put ourselves out there and express ourselves. Why not use Snapchat just to picture my daily stuff like the labs and students? This lets the young generation understand that its a joy, because sometimes they stereotype science as boring, but its really not. If you really love what youre doing, youll enjoy it, she said.I believe its time for the media to put these achievements in the spotlight, and for scientists to use the power of social media to reach larger audiences and inspire future generations.

DUBAI: Nouf Al-Numair, a jet-setting young scientist from Riyadh, is working tirelessly to encourage Saudi youths to take an interest in science, technology, engineering and math (STEM).She could be the perfect role model for those who wish to make a name for themselves in the field, especially considering her call for lab-bound scientists to get out there and show off their achievements on social media.She obtained an MSc and a Ph.D. in bioinformatics and molecular genetics from University College London (UCL).Despite still being in her early 30s, she now works as a bioinformatics and molecular genetics scientist at King Faisal Specialist Hospital and Research Center.She is also an assistant professor at the College of Medicine at Alfaisal University, and is engaged in volunteer work.After pursuing her undergraduate studies in Saudi Arabia, Al-Numair headed to the UK. After my internship at King Faisal Specialist Hospital and Research Center, I spent time rotating between different labs, she told Arab News.It was then that I realized I wanted to explore how two different scientific fields the pathology of molecular genetics and the technology of computer science could merge. At the time of my placement, this approach wasnt available at universities and hospitals in Saudi Arabia.But the fashionable scientist, with perfectly-coiffed hair and a chic abaya, insists the move was about so much more than just her academic dreams.Going abroad and studying there, living there and exposing myself to a different education will enrich me as a person, she said.Everyone can access knowledge on the Internet, in books but the experience itself is one of the main reasons.Al-Numair is especially grateful to her family for supporting her desire to pursue her dream. When a family sees potential, they should really take care of it and polish it to convert this interest into a real thing, she said.But young aspiring innovators who do not have family support should still follow their passions, as it is up to the individual to make it work, she added. I wasnt taught this dream or passion, I practiced it.Al-Numair is now one of the first Saudi scientists to major in molecular genetics and programing biological information, a precise science that enables practitioners to read the future of diseases before they come into existence through genetic mutation.She uses more than seven programing languages to analyze human genes. She has published several papers and has spoken at multiple international conferences.Since I was young, I always thought of myself as a creator, an innovator. Even then, I wanted to be a pioneer of an interesting field, she said.In 2014, Al-Numair was honored by the Saudi ambassador to the UK in a ceremony celebrating outstanding students for their scientific achievements.She decided to return to the Kingdom to pursue a career in STEM as Saudi Arabia is my birth country. Who does not want to return home?In the Kingdom, she works tirelessly to encourage interest in the science and technology sector. Im a member of the MiSK youth community (the Prince Mohammed bin Salman bin Abdul Aziz Foundation). MiSK focuses on the countrys youth and provides different means of fostering talent, creative potential and innovation that paves the way toward opportunities in the arts and sciences, she said, calling on more young people especially women to take part.I hope that more Saudi and Arab women will join the field. This is why Im participating in the #Championofscience campaign and developing videos with the British Council. Were doing this because we believe its important to shed more light on stories of incredible women working in STEM, to inspire the next generation of girls to become leading scientists.British Councils across the Gulf are working to highlight Arab women working in STEM who are making a real difference in terms of research and innovation in their countries.The council invited participants, including Al-Numair, to film a short video explaining why they chose to follow their dreams, in a bid to encourage young people to show an interest in STEM.Writing is good as you can express yourself, but a video, even if its only one minute youre speaking the language of the young generation, and with social media its crazy now, Al-Numair said of the campaign.We as scientists should be out there more. We should use social media and put ourselves out there and express ourselves. Why not use Snapchat just to picture my daily stuff like the labs and students? This lets the young generation understand that its a joy, because sometimes they stereotype science as boring, but its really not. If you really love what youre doing, youll enjoy it, she said.I believe its time for the media to put these achievements in the spotlight, and for scientists to use the power of social media to reach larger audiences and inspire future generations.

Original post:
Should scientists be on social media? Meet the groundbreaking Saudi researcher who thinks so - Arab News

Read More...

If you’re watching the total solar eclipse, don’t forget to wear sunscreen – Yahoo News

August 21st, 2017 12:44 pm

(People use solar film to photograph the first annular eclipse seen in the U.S. since 1994 on May 20, 2012 in Grand Canyon National Park, Arizona.Getty) If you're planning to marvel in the total solar eclipse on August 21, be sure to wear sunscreen especially if you're planning to view itfor a long time.

While you might be more concerned with keeping your eyes safefrom the sun, the hour or two you spend watching the whole process will leave your skin exposed.

"The levels of damaging ultraviolet (UV) light will only be low during the brief, total solar eclipse occurring within the narrow path of totality, in which the sun is completely blocked by the moon," Christin Burd, a Damon Runyon-fundedprofessor molecular genetics at The Ohio State University, told Business Insider in an email. After the totality, "the unblocked UV rays will be intense and could easily result in sunburn," she said.

For the peopleinthe 70-mile-wide streak of the country that will be able to see the total solar eclipse, the buildup to the event will likely take longer than theyexpect, astronomer Amanda Bauer told ScienceAlert.Those who are just popping out for a few minutes to see a partial eclipse, which varies in timing and size across the country, might get away without lathering up.

Here are some otherthings you should bring if you're going to see the total solar eclipse, according to Mark Littman and Fred Espenek, authors of "Totality: The Great American Eclipses of 2017 and 2024."

NOW WATCH: All the nasty things inside a pimple and why you should stop popping them

More From Business Insider

Originally posted here:
If you're watching the total solar eclipse, don't forget to wear sunscreen - Yahoo News

Read More...

Tea vs coffee – which cuppa should you be drinking? – Telegraph.co.uk

August 21st, 2017 12:44 pm

Best for improving bone strength? Tea

Thanks to caffeines slight blocking effect on calcium absorption, coffee is often mistakenly pilloried as contributing to weakened bone density. (In fact, any such effects of caffeine on calcium absorption is so small, it is fully offset by the tiniest splash of milk.)

Conversely, studies have long linked black tea with improved bone strength but, says MacLennan, the benefits of green tea may be even greater.

He cites research from Texas, published in 2013 in the American Journal of Clinical Nutrition: It found that the epigallocatechin (EGCG) compound, which is abundant in green tea, can decrease the numbers of osteoclasts in the body these are the cells that break down bone and increase the numbers and activity of osteoblasts, the cells that build bone. Green tea may also be helpful if you need to speed up the healing process of a broken bone.

Go here to see the original:
Tea vs coffee - which cuppa should you be drinking? - Telegraph.co.uk

Read More...

Page 956«..1020..955956957958..970980..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick